Antibodies specifically directed to a soluble form of CTLA-4

Frank James Ward; Robert Norman Barker; Lekh Nath Dahal

Antibodies specifically directed to a soluble form of CTLA-4

Frank James Ward (Inventor), Robert Norman Barker (Inventor), Lekh Nath Dahal (Inventor)

Research output: Patent

35 Downloads (Pure)

Abstract

The invention provides materials and methods relating to antibodies specific for a soluble form of CTLA-4 (sCLTA-4). Such antibodies have been shown to have a strong boosting effect on antigen-specific human immune responses.

Original language	English
Patent number	US8697845 B2
Priority date	15/04/14
Publication status	Published - 2 Sep 2010

Access to Document

US8697845B2Final published version, 1.39 MBLicence: Unspecified

Antibodies specifically directed to a soluble form of CTLA-4

Fingerprint Dive into the research topics of 'Antibodies specifically directed to a soluble form of CTLA-4'. Together they form a unique fingerprint.

Cite this

Ward, F. J., Barker, R. N., & Dahal, L. N. (2010). Antibodies specifically directed to a soluble form of CTLA-4. (Patent No. US8697845 B2).

@misc{2517a5b375cc4fb4845b576ae597911b,

title = "Antibodies specifically directed to a soluble form of CTLA-4",

abstract = "The invention provides materials and methods relating to antibodies specific for a soluble form of CTLA-4 (sCLTA-4). Such antibodies have been shown to have a strong boosting effect on antigen-specific human immune responses.",

author = "Ward, {Frank James} and Barker, {Robert Norman} and Dahal, {Lekh Nath}",

note = "New antibody molecule that binds specifically to soluble form of cytotoxic T-lymphocyte antigen, useful as vaccine e.g. to enhance antigen specific immune response against pathogens e.g. bacteria, virus e.g. HIV, and nematode Patent Number(s): WO2010097597-A1 Original ; AU2010217453-A1 ; EP2401035-A1 Original ; CN102421482-A ; US2012107320-A1 Original ; CA2772648-A1 ; JP2012518425-W ; IN201106831-P4 ; US8697845-B2 Original ; JP5864266-B2 ; CN102421482-B ; AU2010217453-B2 ; EP2401035-B1 Original ; ES2662652-T3; US8697845 B2",

year = "2010",

month = sep,

day = "2",

language = "English",

type = "Patent",

}

TY - PAT

T1 - Antibodies specifically directed to a soluble form of CTLA-4

AU - Ward, Frank James

AU - Barker, Robert Norman

AU - Dahal, Lekh Nath

N1 - New antibody molecule that binds specifically to soluble form of cytotoxic T-lymphocyte antigen, useful as vaccine e.g. to enhance antigen specific immune response against pathogens e.g. bacteria, virus e.g. HIV, and nematode Patent Number(s): WO2010097597-A1 Original ; AU2010217453-A1 ; EP2401035-A1 Original ; CN102421482-A ; US2012107320-A1 Original ; CA2772648-A1 ; JP2012518425-W ; IN201106831-P4 ; US8697845-B2 Original ; JP5864266-B2 ; CN102421482-B ; AU2010217453-B2 ; EP2401035-B1 Original ; ES2662652-T3

PY - 2010/9/2

Y1 - 2010/9/2

N2 - The invention provides materials and methods relating to antibodies specific for a soluble form of CTLA-4 (sCLTA-4). Such antibodies have been shown to have a strong boosting effect on antigen-specific human immune responses.

AB - The invention provides materials and methods relating to antibodies specific for a soluble form of CTLA-4 (sCLTA-4). Such antibodies have been shown to have a strong boosting effect on antigen-specific human immune responses.

UR - https://worldwide.espacenet.com/publicationDetails/biblio?FT=D&date=20140415&DB=EPODOC&locale=en_EP&CC=US&NR=8697845B2&KC=B2&ND=5

M3 - Patent

M1 - US8697845 B2

ER -